Psoriasis Treatment Market

Psoriasis Treatment Market (Drug Type: Biologics, and Small Molecule Drugs; Types of Psoriasis: Plaque Psoriasis, Inverse Psoriasis, Guttate Psoriasis, Pustular Psoriasis and Others; Type: Branded, and Generic) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

Psoriasis Treatment Market Outlook 2035

  • The global industry was valued at US$ 35.0 Bn in 2024
  • It is projected to grow at a CAGR of 9.5% from 2025 to 2035 and cross US$ 87.6 Bn by the end of 2035

Analysts’ Viewpoint

The global psoriasis treatment market is witnessing steadiness, driven primarily by the increase in prevalence of psoriasis, rising awareness and advancements in biologic and targeted therapies. More number of patients are being diagnosed with psoriasis due to the overall increase in healthcare access and improved awareness, which increases the demand for effective treatment that offers long-term control of symptoms.

Biologic therapies, especially the IL-17 and IL-23 inhibitors, are currently offering highly effective treatment options are accepted by patients and care providers. However, there are key restraints including the high price of these new therapies that are limiting access in low and middle-income areas.

Psoriasis Treatment Market Revenue Growth (USD Bn)

The major opportunities are available particularly in emerging markets as the healthcare infrastructure improves, as well as the emergence of biosimilars in conjunction with more customized forms of treatments with facilitating technology including digital health monitoring and AI diagnostics that can help identify treatment patterns simplifying affordability, access, and effectiveness of therapy. These changes are a fast-moving landscape offering an opportunity for pharmaceutical companies in gaining new ground and ultimately helping patients.

Market Introduction

Psoriasis is an autoimmune condition that causes inflammation in skin. Symptoms of psoriasis include thick areas of discolored skin covered with scales. These thick, scaly areas are called plaques. Psoriasis is a chronic skin condition, which means it can flare up unexpectedly and there’s no cure. Psoriasis treatment market aim to stop skin cells from growing so quickly and to remove scales. Options include creams and ointments (topical therapy), light therapy (phototherapy), and oral or injected medications.

Attribute Detail
Market Drivers
  • Rising Prevalence of Psoriasis
  • Increasing regulatory approvals

Rising Prevalence of Psoriasis to Drive Psoriasis Treatment Market Size

The increasing incidence of psoriasis is a significant driver to the growth of the psoriasis treatment market around the world. For instance, according to data published by National Center for Biotechnology Information in 2022, Psoriasis is a common chronic inflammatory disease with prevalence of 0.33%-0.6% in different races and affects around 125 million people worldwide. This growing patient pool of psoriasis, their need for more innovative treatments to manage symptoms of inflammation, red lesions, and plaques, the pressure for drugs geared toward symptom relief is increasing along with the size of the patient pool.

The increasing incidence of comorbidities including psoriatic arthritis (which occurs in 30 to 40% of psoriasis patients) will only serve to increase the need for potential therapies. Along with increased disease awareness, diagnosis, and access, the residual population seeking treatment is well defined and follow-up consultation will continue to grow.

Increasing Regulatory Approvals Anticipated to Boost Psoriasis Treatment Market Expansion

The increasing regulatory approvals is a key driver to the psoriasis treatment industry growth as they are allowing for more advanced innovative therapies, specifically biologics and new small molecules, to be developed to provide better efficacy and safety for patients. With more innovative products such as newer interleukin inhibitors and topical products approved by regulatory agencies, patients will have a greater range of effective treatment options to treat their unmet medical needs to manage their disease.

For instance, in May 2025, Arcutis Biotherapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis

Furthermore, with the approval of these new therapies, there will be more new products for competition, continued development and research, and biopharmaceutical industry investment, all contributing to strong growth in the market over the forecast period.

Biologics Segment is Dominating Psoriasis Treatment Market

Based on drug type, biologics is expected to be the dominating segment in psoriasis treatment market. This is due to biologics providing superior efficacy, prolonged duration/high sustained response rates, and ability to target the components of the immune system related to the inflammation processes associated with psoriasis. Evidence indicates that biologics, particularly interleukin inhibitors (IL-17 and IL-23 inhibitors), lead to improvements in skin clearance and quality of life for moderate to severe forms of psoriasis compared to systemic therapies.

Psoriasis Treatment Market Share By Product Type 2024

The targeted mechanism of action of biologics produces fewer systemic side-effects and improved adherence to therapy. Biologics are further gaining traction in psoriasis treatment through clinical trials, regulatory approvals, as well as awareness of biologics among healthcare providers and patients. With this momentum, biologics will continue to represent the largest portion of growth in this market over the next few years.

Regional Outlook of Psoriasis Treatment Market

Attribute Detail
Leading Region North America

North America has a strong hold on the market due to its better healthcare facilities, higher prevalence of psoriasis, and emphasis on novel therapies. The U. S., in particular, dominates the North American market, accounting for a large population who have points of plaque psoriasis and psoriatic arthritis, and thus increased demand for newer advance psoriasis treatment market options.

The primary form of biologics treatment are TNF inhibitors and interleukin inhibitors, and there is also an increasing accessibility to new drugs as more are approved. Challenges exist in terms of reimbursement, regulatory processes, and competition, but overall, North America and its non-problematic advanced technologies, coupled with the many acclaims from sponsors and overall supportive research and development from the leading pharmaceutical companies solidifies North America's lead in the market.

Psoriasis Treatment Market Regional Analysis In 2024

There are also awareness initiatives, such as Psoriasis Awareness Month, which educate patients about their disease and increase treatment uptake. All these trends are creating new opportunities for patient stratification - specifically around biologics - despite the product pricing being higher and impacting patient accessibility overall. The continued development of, and access to, innovative medicines coupled with the growing focus on medical innovation would likely mitigate low product performance.

Analysis of Key Players in Psoriasis Treatment Market

AbbVie Inc, Amgen Inc, AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim Pharmaceuticals, Inc., Arcutis Biotherapeutics, Inc., Dermavant Sciences, Inc., TIEFENBACHER GROUP, UCB S.A., Bausch Health, Sun Pharmaceutical Industries Limited, Akeso Biopharma Co., Ltd are some of the leading players operating in the global psoriasis treatment market.

Each of these players has been profiled in the psoriasis treatment market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments

  • In August 2024, Amgen announced Otezla (apremilast) is available in the U.S. for pediatric use. Otezla is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 Kg (44 lb) and are candidates for phototherapy or systemic therapy. There are currently no other FDA-approved oral medications for moderate to severe plaque psoriasis in this patient population.
  • In September 2022, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Psoriasis Treatment Market Snapshot

Attribute Detail
Size in 2024 US$ 35.0 Bn
Forecast Value in 2035 US$ 87.6 Bn
CAGR 9.5%
Forecast Period 2025-2035
Historical Data Available for 2020-2023
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape
  • Competition Matrix
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Segmentation
  • Drug Type
    • Biologics
      • TNF Inhibitors
      • Interleukin Inhibitors
        • IL-17 Inhibitors
        • IL-23 Inhibitors
        • Others (IL-36 Receptor Antagonist, IL-12/23 Inhibitor, etc.)
    • Small Molecule Drugs
      • Tyrosine kinase 2 (TYK2) inhibitors
      • Phosphodiesterase 4 (PDE4) inhibitor
      • Corticosteroids
      • Retinoids
      • Calcineurin inhibitors
      • Others (Vitamin D analogues, aryl hydrocarbon receptor (AHR) agonist, Anthralin, Salicylic acid, Methotrexate, Cyclosporine, etc.)
  • Type
    • Branded
    • Generic
  • Types of Psoriasis
    • Plaque Psoriasis
    • Inverse Psoriasis
    • Guttate Psoriasis
    • Pustular Psoriasis
    • Others (Erythrodermic Psoriasis, Sebopsoriasis, Nail psoriasis, etc.)
  • Route of Administration
    • Oral
    • Topical
    • Parenteral
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • The Netherlands
  • Switzerland
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • Brazil
  • Mexico
  • Argentina
  • GCC Countries
  • South Africa
Companies Profiled
  • Bristol-Myers Squibb Company
  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Merck & Co., Inc.,
  • Novartis AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Arcutis Biotherapeutics, Inc
  • Dermavant Sciences, Inc.
  • TIEFENBACHER GROUP
  • UCB S.A.
  • Bausch Health
  • Sun Pharmaceutical Industries Limited
  • Akeso Biopharma Co., Ltd.
  • Other Prominent Players
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global psoriasis treatment market in 2024?

It was valued at US$ 35.0 Bn in 2024.

What is the projected size of the psoriasis treatment market by 2035?

It is projected to reach US$ 87.6 Bn by the end of 2035.

What are the factors driving the psoriasis treatment market?

Rising Prevalence of Psoriasis and Increasing regulatory approvals.

What is the psoriasis treatment industry expected to grow during the forecast period?

It is anticipated to grow at a CAGR of 9.5% from 2025 to 2035.

Which region is expected to dominate the psoriasis treatment market during the forecast period?

North America is expected to account for the largest share from 2025 to 2035.

Who are the prominent psoriasis treatment providers?

AbbVie Inc, Amgen Inc, AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim Pharmaceuticals, Inc., Arcutis Biotherapeutics, Inc., Dermavant Sciences, Inc., TIEFENBACHER GROUP, UCB S.A., Bausch Health, Sun Pharmaceutical Industries Limited, Akeso Biopharma Co., and Other prominent players.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Psoriasis Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Psoriasis Treatment Market Analysis and Forecasts, 2020 to 2035

        4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

    5.1. Regulatory Landscape across Key Regions / Countries

    5.2. Psoriasis Treatment Market Trends

    5.3. PORTER’s Five Forces Analysis

    5.4. PESTEL Analysis

    5.5. Key Purchase Metrics for End-users

    5.6. Brand and Pricing Analysis

    5.7. Treatment Algorithm

    5.8. Distributors Landscape

6. Global Psoriasis Treatment Market Analysis and Forecasts, By Drug Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast By Drug Type, 2020 to 2035

        6.3.1. Biologics

            6.3.1.1. TNF Inhibitors

            6.3.1.2. Interleukin Inhibitors

                6.3.1.2.1. IL-17 Inhibitors

                6.3.1.2.2. IL-23 Inhibitors

                6.3.1.2.3. Others

        6.3.2. Small Molecule Drugs

            6.3.2.1. Tyrosine kinase 2 (TYK2) inhibitors

            6.3.2.2. Phosphodiesterase 4 (PDE4) inhibitor

            6.3.2.3. Corticosteroids

            6.3.2.4. Retinoids

            6.3.2.5. Calcineurin inhibitors

            6.3.2.6. Others

    6.4. Market Attractiveness By Drug Type

7. Global Psoriasis Treatment Market Analysis and Forecasts, By Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast By Type, 2020 to 2035

        7.3.1. Branded

        7.3.2. Generic

    7.4. Market Attractiveness By Type

8. Global Psoriasis Treatment Market Analysis and Forecasts, By Types of Psoriasis

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast By Types of Psoriasis, 2020 to 2035

        8.3.1. Plaque Psoriasis

        8.3.2. Inverse Psoriasis

        8.3.3. Guttate Psoriasis

        8.3.4. Pustular Psoriasis

        8.3.5. Others

    8.4. Market Attractiveness By Types of Psoriasis

9. Global Psoriasis Treatment Market Analysis and Forecasts, By Route of Administration

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast By Route of Administration, 2020 to 2035

        9.3.1. Oral

        9.3.2. Topical

        9.3.3. Parenteral

    9.4. Market Attractiveness By Route of Administration

10. Global Psoriasis Treatment Market Analysis and Forecasts, By Distribution Channel

    10.1. Introduction & Definition

    10.2. Key Findings / Developments

    10.3. Market Value Forecast By Distribution Channel, 2020 to 2035

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Market Attractiveness By Distribution Channel

11. Global Psoriasis Treatment Market Analysis and Forecasts, By Region

    11.1. Key Findings

    11.2. Market Value Forecast By Region

        11.2.1. North America

        11.2.2. Europe

        11.2.3. Asia Pacific

        11.2.4. Latin America

        11.2.5. Middle East & Africa

    11.3. Market Attractiveness By Region

12. North America Psoriasis Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast By Drug Type, 2020 to 2035

        12.2.1. Biologics

            12.2.1.1. TNF Inhibitors

            12.2.1.2. Interleukin Inhibitors

                12.2.1.2.1. IL-17 Inhibitors

                12.2.1.2.2. IL-23 Inhibitors

                12.2.1.2.3. Others

        12.2.2. Small Molecule Drugs

            12.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors

            12.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor

            12.2.2.3. Corticosteroids

            12.2.2.4. Retinoids

            12.2.2.5. Calcineurin inhibitors

            12.2.2.6. Others

    12.3. Market Value Forecast By Type, 2020 to 2035

        12.3.1. Branded

        12.3.2. Generic

    12.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035

        12.4.1. Plaque Psoriasis

        12.4.2. Inverse Psoriasis

        12.4.3. Guttate Psoriasis

        12.4.4. Pustular Psoriasis

        12.4.5. Others

    12.5. Market Value Forecast By Route of Administration, 2020 to 2035

        12.5.1. Oral

        12.5.2. Topical

        12.5.3. Topical

    12.6. Market Value Forecast By Distribution Channel, 2020 to 2035

        12.6.1. Hospital Pharmacies

        12.6.2. Retail Pharmacies

        12.6.3. Online Pharmacies

    12.7. Market Value Forecast By Country, 2020 to 2035

        12.7.1. U.S.

        12.7.2. Canada

    12.8. Market Attractiveness Analysis

        12.8.1. By Drug Type

        12.8.2. By Type

        12.8.3. By Types of Psoriasis

        12.8.4. By Route of Administration

        12.8.5. By Distribution Channel

        12.8.6. By Country

13. Europe Psoriasis Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast By Drug Type, 2020 to 2035

        13.2.1. Biologics

            13.2.1.1. TNF Inhibitors

            13.2.1.2. Interleukin Inhibitors

                13.2.1.2.1. IL-17 Inhibitors

                13.2.1.2.2. IL-23 Inhibitors

                13.2.1.2.3. Others

        13.2.2. Small Molecule Drugs

            13.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors

            13.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor

            13.2.2.3. Corticosteroids

            13.2.2.4. Retinoids

            13.2.2.5. Calcineurin inhibitors

            13.2.2.6. Others

    13.3. Market Value Forecast By Type, 2020 to 2035

        13.3.1. Branded

        13.3.2. Generic

    13.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035

        13.4.1. Plaque Psoriasis

        13.4.2. Inverse Psoriasis

        13.4.3. Guttate Psoriasis

        13.4.4. Pustular Psoriasis

        13.4.5. Others

    13.5. Market Value Forecast By Route of Administration, 2020 to 2035

        13.5.1. Oral

        13.5.2. Topical

        13.5.3. Topical

    13.6. Market Value Forecast By Distribution Channel, 2020 to 2035

        13.6.1. Hospital Pharmacies

        13.6.2. Retail Pharmacies

        13.6.3. Online Pharmacies

    13.7. Market Value Forecast By Country/Sub-region, 2020 to 2035

        13.7.1. Germany

        13.7.2. U.K.

        13.7.3. France

        13.7.4. Italy

        13.7.5. Spain

        13.7.6. Switzerland

        13.7.7. The Netherlands

        13.7.8. Rest of Europe

    13.8. Market Attractiveness Analysis

        13.8.1. By Drug Type

        13.8.2. By Type

        13.8.3. By Types of Psoriasis

        13.8.4. By Route of Administration

        13.8.5. By Distribution Channel

        13.8.6. By Country/Sub-region

14. Asia Pacific Psoriasis Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast By Drug Type, 2020 to 2035

        14.2.1. Biologics

            14.2.1.1. TNF Inhibitors

            14.2.1.2. Interleukin Inhibitors

                14.2.1.2.1. IL-17 Inhibitors

                14.2.1.2.2. IL-23 Inhibitors

                14.2.1.2.3. Others

        14.2.2. Small Molecule Drugs

            14.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors

            14.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor

            14.2.2.3. Corticosteroids

            14.2.2.4. Retinoids

            14.2.2.5. Calcineurin inhibitors

            14.2.2.6. Others

    14.3. Market Value Forecast By Type, 2020 to 2035

        14.3.1. Branded

        14.3.2. Generic

    14.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035

        14.4.1. Plaque Psoriasis

        14.4.2. Inverse Psoriasis

        14.4.3. Guttate Psoriasis

        14.4.4. Pustular Psoriasis

        14.4.5. Others

    14.5. Market Value Forecast By Route of Administration, 2020 to 2035

        14.5.1. Oral

        14.5.2. Topical

        14.5.3. Topical

    14.6. Market Value Forecast By Distribution Channel, 2020 to 2035

        14.6.1. Hospital Pharmacies

        14.6.2. Retail Pharmacies

        14.6.3. Online Pharmacies

    14.7. Market Value Forecast By Country/Sub-region, 2020 to 2035

        14.7.1. China

        14.7.2. Japan

        14.7.3. India

        14.7.4. Australia & New Zealand

        14.7.5. South Korea

        14.7.6. Rest of Asia Pacific

    14.8. Market Attractiveness Analysis

        14.8.1. By Drug Type

        14.8.2. By Type

        14.8.3. By Types of Psoriasis

        14.8.4. By Route of Administration

        14.8.5. By Distribution Channel

        14.8.6. By Country/Sub-region

15. Latin America Psoriasis Treatment Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast By Drug Type, 2020 to 2035

        15.2.1. Biologics

            15.2.1.1. TNF Inhibitors

            15.2.1.2. Interleukin Inhibitors

                15.2.1.2.1. IL-17 Inhibitors

                15.2.1.2.2. IL-23 Inhibitors

                15.2.1.2.3. Others

        15.2.2. Small Molecule Drugs

            15.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors

            15.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor

            15.2.2.3. Corticosteroids

            15.2.2.4. Retinoids

            15.2.2.5. Calcineurin inhibitors

            15.2.2.6. Others

    15.3. Market Value Forecast By Type, 2020 to 2035

        15.3.1. Branded

        15.3.2. Generic

    15.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035

        15.4.1. Plaque Psoriasis

        15.4.2. Inverse Psoriasis

        15.4.3. Guttate Psoriasis

        15.4.4. Pustular Psoriasis

        15.4.5. Others

    15.5. Market Value Forecast By Route of Administration, 2020 to 2035

        15.5.1. Oral

        15.5.2. Topical

        15.5.3. Topical

    15.6. Market Value Forecast By Distribution Channel, 2020 to 2035

        15.6.1. Hospital Pharmacies

        15.6.2. Retail Pharmacies

        15.6.3. Online Pharmacies

    15.7. Market Value Forecast By Country/Sub-region, 2020 to 2035

        15.7.1. Brazil

        15.7.2. Mexico

        15.7.3. Argentina

        15.7.4. Rest of Latin America

    15.8. Market Attractiveness Analysis

        15.8.1. By Drug Type

        15.8.2. By Type

        15.8.3. By Types of Psoriasis

        15.8.4. By Route of Administration

        15.8.5. By Distribution Channel

        15.8.6. By Country/Sub-region

16. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast

    16.1. Introduction

        16.1.1. Key Findings

    16.2. Market Value Forecast By Drug Type, 2020 to 2035

        16.2.1. Biologics

            16.2.1.1. TNF Inhibitors

            16.2.1.2. Interleukin Inhibitors

                16.2.1.2.1. IL-17 Inhibitors

                16.2.1.2.2. IL-23 Inhibitors

                16.2.1.2.3. Others

        16.2.2. Small Molecule Drugs

            16.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors

            16.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor

            16.2.2.3. Corticosteroids

            16.2.2.4. Retinoids

            16.2.2.5. Calcineurin inhibitors

            16.2.2.6. Others

    16.3. Market Value Forecast By Type, 2020 to 2035

        16.3.1. Branded

        16.3.2. Generic

    16.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035

        16.4.1. Plaque Psoriasis

        16.4.2. Inverse Psoriasis

        16.4.3. Guttate Psoriasis

        16.4.4. Pustular Psoriasis

        16.4.5. Others

    16.5. Market Value Forecast By Route of Administration, 2020 to 2035

        16.5.1. Oral

        16.5.2. Topical

        16.5.3. Topical

    16.6. Market Value Forecast By Distribution Channel, 2020 to 2035

        16.6.1. Hospital Pharmacies

        16.6.2. Retail Pharmacies

        16.6.3. Online Pharmacies

    16.7. Market Value Forecast By Country/Sub-region, 2020 to 2035

        16.7.1. GCC Countries

        16.7.2. South Africa

        16.7.3. Rest of Middle East & Africa

    16.8. Market Attractiveness Analysis

        16.8.1. By Drug Type

        16.8.2. By Type

        16.8.3. By Types of Psoriasis

        16.8.4. By Route of Administration

        16.8.5. By Distribution Channel

        16.8.6. By Country/Sub-region

17. Competition Landscape

    17.1. Market Player – Competition Matrix (By Tier and Size of companies)

    17.2. Market Share Analysis By Company (2024)

    17.3. Company Profiles

        17.3.1. Bristol-Myers Squibb Company

            17.3.1.1. Company Overview

            17.3.1.2. Financial Overview

            17.3.1.3. Product Portfolio

            17.3.1.4. Business Strategies

            17.3.1.5. Recent Developments

        17.3.2. AbbVie Inc

            17.3.2.1. Company Overview

            17.3.2.2. Financial Overview

            17.3.2.3. Product Portfolio

            17.3.2.4. Business Strategies

            17.3.2.5. Recent Developments

        17.3.3. Amgen Inc

            17.3.3.1. Company Overview

            17.3.3.2. Financial Overview

            17.3.3.3. Product Portfolio

            17.3.3.4. Business Strategies

            17.3.3.5. Recent Developments

        17.3.4. AstraZeneca

            17.3.4.1. Company Overview

            17.3.4.2. Financial Overview

            17.3.4.3. Product Portfolio

            17.3.4.4. Business Strategies

            17.3.4.5. Recent Developments

        17.3.5. Eli Lilly and Company

            17.3.5.1. Company Overview

            17.3.5.2. Financial Overview

            17.3.5.3. Product Portfolio

            17.3.5.4. Business Strategies

            17.3.5.5. Recent Developments

        17.3.6. Johnson & Johnson Services, Inc.

            17.3.6.1. Company Overview

            17.3.6.2. Financial Overview

            17.3.6.3. Product Portfolio

            17.3.6.4. Business Strategies

            17.3.6.5. Recent Developments

        17.3.7. LEO Pharma A/S

            17.3.7.1. Company Overview

            17.3.7.2. Financial Overview

            17.3.7.3. Product Portfolio

            17.3.7.4. Business Strategies

            17.3.7.5. Recent Developments

        17.3.8. Merck & Co., Inc.,

            17.3.8.1. Company Overview

            17.3.8.2. Financial Overview

            17.3.8.3. Product Portfolio

            17.3.8.4. Business Strategies

            17.3.8.5. Recent Developments

        17.3.9. Novartis AG

            17.3.9.1. Company Overview

            17.3.9.2. Financial Overview

            17.3.9.3. Product Portfolio

            17.3.9.4. Business Strategies

            17.3.9.5. Recent Developments

        17.3.10. Boehringer Ingelheim Pharmaceuticals, Inc.

            17.3.10.1. Company Overview

            17.3.10.2. Financial Overview

            17.3.10.3. Product Portfolio

            17.3.10.4. Business Strategies

            17.3.10.5. Recent Developments

        17.3.11. Arcutis Biotherapeutics, Inc

            17.3.11.1. Company Overview

            17.3.11.2. Financial Overview

            17.3.11.3. Product Portfolio

            17.3.11.4. Business Strategies

            17.3.11.5. Recent Developments

        17.3.12. Dermavant Sciences, Inc.

            17.3.12.1. Company Overview

            17.3.12.2. Financial Overview

            17.3.12.3. Product Portfolio

            17.3.12.4. Business Strategies

            17.3.12.5. Recent Developments

        17.3.13. TIEFENBACHER GROUP

            17.3.13.1. Company Overview

            17.3.13.2. Financial Overview

            17.3.13.3. Product Portfolio

            17.3.13.4. Business Strategies

            17.3.13.5. Recent Developments

        17.3.14. UCB S.A.

            17.3.14.1. Company Overview

            17.3.14.2. Financial Overview

            17.3.14.3. Product Portfolio

            17.3.14.4. Business Strategies

            17.3.14.5. Recent Developments

        17.3.15. Bausch Health

            17.3.15.1. Company Overview

            17.3.15.2. Financial Overview

            17.3.15.3. Product Portfolio

            17.3.15.4. Business Strategies

            17.3.15.5. Recent Developments

        17.3.16. Sun Pharmaceutical Industries Limited

            17.3.16.1. Company Overview

            17.3.16.2. Financial Overview

            17.3.16.3. Product Portfolio

            17.3.16.4. Business Strategies

            17.3.16.5. Recent Developments

        17.3.17. Akeso Biopharma Co., Ltd.

            17.3.17.1. Company Overview

            17.3.17.2. Financial Overview

            17.3.17.3. Product Portfolio

            17.3.17.4. Business Strategies

            17.3.17.5. Recent Developments

List of Tables

Table 01: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035

Table 02: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035

Table 03: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035

Table 04: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035

Table 05: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035

Table 06: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035

Table 07: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035

Table 08: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Region, 2020 to 2035

Table 09: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country, 2020-2035

Table 10: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035

Table 11: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035

Table 12: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035

Table 13: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035

Table 14: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035

Table 15: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035

Table 16: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035

Table 17: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035

Table 18: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035

Table 19: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035

Table 20: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035

Table 21: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035

Table 22: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035

Table 23: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035

Table 24: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035

Table 25: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035

Table 26: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035

Table 27: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035

Table 28: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035

Table 29: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035

Table 30: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035

Table 31: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035

Table 32: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035

Table 33: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035

Table 34: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035

Table 35: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035

Table 36: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035

Table 37: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035

Table 38: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035

Table 39: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035

Table 40: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035

Table 41: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035

Table 42: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035

Table 43: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035

Table 44: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035

Table 45: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035

Table 46: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035

Table 47: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035

Table 48: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035

List of Figures

Figure 01: Global Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035

Figure 02: Global Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035

Figure 03: Global Psoriasis Treatment Market Revenue (US$ Bn), by Biologics, 2020 to 2035

Figure 04: Global Psoriasis Treatment Market Revenue (US$ Bn), by Small Molecule Drugs, 2020 to 2035

Figure 05: Global Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035

Figure 06: Global Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035

Figure 07: Global Psoriasis Treatment Market Revenue (US$ Bn), by Branded, 2020 to 2035

Figure 08: Global Psoriasis Treatment Market Revenue (US$ Bn), by Generics, 2020 to 2035

Figure 09: Global Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035

Figure 10: Global Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035

Figure 11: Global Psoriasis Treatment Market Revenue (US$ Bn), by Plaque Psoriasis, 2020 to 2035

Figure 12: Global Psoriasis Treatment Market Revenue (US$ Bn), by Inverse Psoriasis, 2020 to 2035

Figure 13: Global Psoriasis Treatment Market Revenue (US$ Bn), by Guttate Psoriasis, 2020 to 2035

Figure 14: Global Psoriasis Treatment Market Revenue (US$ Bn), by Pustular Psoriasis, 2020 to 2035

Figure 15: Global Psoriasis Treatment Market Revenue (US$ Bn), by Others, 2020 to 2035

Figure 16: Global Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035

Figure 17: Global Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035

Figure 18: Global Psoriasis Treatment Market Revenue (US$ Bn), by Oral, 2020 to 2035

Figure 19: Global Psoriasis Treatment Market Revenue (US$ Bn), by Topical, 2020 to 2035

Figure 20: Global Psoriasis Treatment Market Revenue (US$ Bn), by Parenteral, 2020 to 2035

Figure 21: Global Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035

Figure 22: Global Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035

Figure 23: Global Psoriasis Treatment Market Revenue (US$ Bn), by Hospital Pharmacies, 2020 to 2035

Figure 24: Global Psoriasis Treatment Market Revenue (US$ Bn), by Retail Pharmacies, 2020 to 2035

Figure 25: Global Psoriasis Treatment Market Revenue (US$ Bn), by Online Pharmacies, 2020 to 2035

Figure 26: Global Psoriasis Treatment Market Value Share Analysis, By Region, 2024 and 2035

Figure 27: Global Psoriasis Treatment Market Attractiveness Analysis, By Region, 2025 to 2035

Figure 28: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035

Figure 29: North America Psoriasis Treatment Market Value Share Analysis, by Country, 2024 and 2035

Figure 30: North America Psoriasis Treatment Market Attractiveness Analysis, by Country, 2025 to 2035

Figure 31: North America Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035

Figure 32: North America Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035

Figure 33: North America Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035

Figure 34: North America Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035

Figure 35: North America Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035

Figure 36: North America Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035

Figure 37: North America Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035

Figure 38: North America Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035

Figure 39: North America Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035

Figure 40: North America Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035

Figure 41: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035

Figure 42: Europe Psoriasis Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035

Figure 43: Europe Psoriasis Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035

Figure 44: Europe Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035

Figure 45: Europe Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035

Figure 46: Europe Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035

Figure 47: Europe Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035

Figure 48: Europe Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035

Figure 49: Europe Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035

Figure 50: Europe Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035

Figure 51: Europe Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035

Figure 52: Europe Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035

Figure 53: Europe Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035

Figure 54: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035

Figure 55: Asia Pacific Psoriasis Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035

Figure 56: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035

Figure 57: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035

Figure 58: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035

Figure 59: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035

Figure 60: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035

Figure 61: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035

Figure 62: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035

Figure 63: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035

Figure 64: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035

Figure 65: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035

Figure 66: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035

Figure 67: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035

Figure 68: Latin America Psoriasis Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035

Figure 69: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035

Figure 70: Latin America Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035

Figure 71: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035

Figure 72: Latin America Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035

Figure 73: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035

Figure 74: Latin America Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035

Figure 75: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035

Figure 76: Latin America Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035

Figure 77: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035

Figure 78: Latin America Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035

Figure 79: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035

Figure 80: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035

Figure 81: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035

Figure 82: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035

Figure 83: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035

Figure 84: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035

Figure 85: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035

Figure 86: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035

Figure 87: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035

Figure 88: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035

Figure 89: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035

Figure 90: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035

Figure 91: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035

Figure 92: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035

Copyright © Transparency Market Research, Inc. All Rights reserved